Exclusive: Reid Huber reunites with former Incyte colleague Wenqing Yao, backs Synnovation with $102M for three trials
After spending nearly 20 years together in leadership roles at Incyte, helping bring to market five medicines, Wenqing Yao and Reid Huber are reuniting on a new biotech venture that will enter the clinic in the next few weeks.
The mission is quite personal for Yao, who’s a cancer survivor of almost 10 years. He’s also lost both parents, a few cousins and a close colleague to cancer.
With that, Yao’s new biotech, Synnovation Therapeutics, aims to make best-in-class medicines that improve upon current treatment classes, starting with PARP1 inhibitors, PI3K alpha and a third undisclosed target. The Wilmington, DE-based biotech will have three small molecule drugs in the clinic around this time next year, Yao, Synnovation’s CEO, told Endpoints News in an interview.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
